Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study

Nephrology

Volumn 20, Issue 9, 2015, Pages 601-608

  Iimori, Soichiro ^a   Naito, Shotaro ^a   Noda, Yumi ^b   Nishida, Hidenori ^c   Kihira, Hiromi ^d   Yui, Naofumi ^a   Okado, Tomokazu ^a   Sasaki, Sei ^a   Uchida, Shinichi ^a   Rai, Tatemitsu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Nakano General Hospital   (Japan)

^c TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^d Hiratsuka Kyosai Hospital   (Japan)

Author keywords

anaemia; cardiovascular disease; chronic kidney disease; iron deficiency; mortality

Indexed keywords

ANTIANEMIC AGENT; IRON; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; END STAGE RENAL DISEASE; FEMALE; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; JAPAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; ANEMIA, IRON-DEFICIENCY; BLOOD; CARDIOVASCULAR DISEASE; CHI SQUARE DISTRIBUTION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIETARY SUPPLEMENT; DISEASE COURSE; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIMARY HEALTH CARE; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; BIOMARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; FEMALE; HEMATINICS; HUMANS; IRON; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRIMARY HEALTH CARE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84939446274     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12493     Document Type: Article

References (27)

1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J,. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch. Intern. Med. 2002; 162: 1401-1408.
2. Sarnak MJ, Tighiouart H, Manjunath G, et al. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J. Am. Coll. Cardiol. 2002; 40: 27-33.
3. Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM,. Association of high serum creatinine and anemia increases the risk of coronary events: Results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J. Am. Soc. Nephrol. 2003; 14: 2919-2925.
4. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W,. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: The ARIC Study. Kidney Int. 2003; 64: 610-615.
5. KDIGO. KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int. Suppl. 2012; 2: 279-335.
6. Fishbane S, Pollack S, Feldman HI, Joffe MM,. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin. J. Am. Soc. Nephrol. 2009; 4: 57-61.
7. Iimori S, Noda Y, Okado T, et al. Baseline characteristics and prevalence of cardiovascular disease in newly visiting or referred chronic kidney disease patients to nephrology centers in Japan: A prospective cohort study. BMC Nephrol. 2013; 14: 152.
8. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.
9. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 2009; 53: 982-992.
10. Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. Clin. Exp. Nephrol. 2009; 13: 537-566.
11. Japanese Society of Nephrology. Special issue: Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Nihon Jinzo Gakkai shi 2012; 54: 1034-1191.
12. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant. 2004; 19: 121-132.
13. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE,. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am. J. Kidney Dis. 1996; 28: 53-61.
14. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int. 2003; 63: 1499-1507.
15. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R,. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J. Am. Soc. Nephrol. 2002; 13: 1928-1936.
16. Langston RD, Presley R, Flanders WD, McClellan WM,. Renal insufficiency and anemia are independent risk factors for death among patients with acute myocardial infarction. Kidney Int. 2003; 64: 1398-1405.
17. Fink J, Blahut S, Reddy M, Light P,. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am. J. Kidney Dis. 2001; 37: 348-355.
18. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ,. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am. J. Kidney Dis. 2002; 40: 1153-1161.
19. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am. J. Kidney Dis. 2000; 35: 250-256.
20. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A,. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am. J. Kidney Dis. 1997; 29: 541-548.
21. Kovesdy CP, Estrada W, Ahmadzadeh S, Kalantar-Zadeh K,. Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009; 4: 435-441.
22. Dunn LL, Suryo Rahmanto Y, Richardson DR,. Iron uptake and metabolism in the new millennium. Trends Cell Biol. 2007; 17: 93-100.
23. Brownlie T, Utermohlen V, Hinton PS, Haas JD,. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am. J. Clin. Nutr. 2004; 79: 437-443.
24. Dong F, Zhang X, Culver B, Chew HG Jr, Kelley RO, Ren J,. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: Involvement of nitric oxide synthase and protein tyrosine nitration. Clin. Sci. 2005; 109: 277-286.
25. Minutolo R, Locatelli F, Gallieni M, et al. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: A multicentre prospective study in renal clinics. Nephrol. Dial. Transplant. 2013; 28: 3035-3045.
26. Cases-Amenos A, Martinez-Castelao A, Fort-Ros J, et al. Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study. Nefrologia 2014; 34: 189-198.
27. Akizawa T, Makino H, Matsuo S, et al. Management of anemia in chronic kidney disease patients: Baseline findings from Chronic Kidney Disease Japan Cohort Study. Clin. Exp. Nephrol. 2011; 15: 248-257.